To ask the Secretary of State for Health and Social Care, with reference to the Answer of 27 January 2021 to Question 137239 on Prescription Drugs, what information his Department holds on the number of patients who have been prescribed drugs categorised under the (a) (i) clonazepam and (ii) other benzodiazepines, (b) z-drugs, (c) antidepressants, (d) opioids, (e) pregabalin and (f) gabapentin drug groups in the (A) last 12 months and (B) the previous 12 month period for which data is available.
Answered on
24 February 2025
The following table shows the number of items dispensed and claimed for reimbursement for each of the categories requested, covering the most recently published 12-month period and the 12 months prior:
Drug group | Financial year | Total number of items |
Clonazepam | 2022/23 | 1,048,081 |
2023/24 | 1,059,421 | |
Other benzodiazepines | 2022/23 | 7,156,845 |
2023/24 | 6,814,129 | |
Clonazepam and other benzodiazepines | 2022/23 | 8,204,926 |
2023/24 | 7,873,550 | |
Z-drugs | 2022/23 | 5,316,627 |
2023/24 | 5,113,574 | |
Antidepressants | 2022/23 | 86,263,722 |
2023/24 | 89,131,582 | |
Opioids | 2022/23 | 39,401,517 |
2023/24 | 39,046,206 | |
Pregabalin | 2022/23 | 8,775,699 |
2023/24 | 9,180,793 | |
Gabapentin | 2022/23 | 7,413,759 |
2023/24 | 7,408,375 |
Source: NHS Business Services Authority.
In addition, the following table shows the patient identifiable information for the number of items dispensed and claimed for reimbursement for each of the categories requested, for the most recently published 12-month period and the 12 months prior:
Drug group | Financial Year | Total number of unique identified patients | Percentage of items where the patient has been identified |
Clonazepam | 2022/23 | 85,613 | 98.22% |
2023/24 | 85,191 | 98.16% | |
Other benzodiazepines | 2022/23 | 1,253,962 | 97.06% |
2023/24 | 1,186,001 | 97.01% | |
Clonazepam and other benzodiazepines | 2022/23 | 1,324,792 | 97.21% |
2023/24 | 1,256,941 | 97.17% | |
Z-drugs | 2022/23 | 795,959 | 98.29% |
2023/24 | 764,743 | 98.27% | |
Antidepressants | 2022/23 | 8,563,148 | 99.16% |
2023/24 | 8,747,095 | 99.22% | |
Opioids | 2022/23 | 5,593,035 | 98.92% |
2023/24 | 5,562,718 | 98.94% | |
Pregabalin | 2022/23 | 786,403 | 99.36% |
2023/24 | 823,231 | 99.41% | |
Gabapentin | 2022/23 | 808,562 | 99.36% |
2023/24 | 799,144 | 99.41 |
Source: NHS Business Services Authority.
Notes:
- for clonazepam and other benzodiazepines, this is the number of unique patients who have received any combination of clonazepam and/or other benzodiazepines, and no patient is counted twice even where multiple medications have been received;
- the figures for pregabalin and gabapentin refer to the combined category of gabapentinoids; and
- the data in this answer in both tables on opioids, is not directly comparable to data from the previous Parliamentary Questions, PQ137238 and PQ137239, referenced in the question, as these tables refer to opioids in general, while the previous Parliamentary Questions referred to opioid analgesics only.